Search details
1.
Low Cell Bioenergetic Metabolism Characterizes Chronic Lymphocytic Leukemia Patients with Unfavorable Genetic Factors and with a Better Response to BTK Inhibition.
Curr Issues Mol Biol
; 46(6): 5085-5099, 2024 May 22.
Article
in English
| MEDLINE | ID: mdl-38920977
2.
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.
Hematol Oncol
; 42(1): e3249, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-38287529
3.
Persistence of monoclonal B-cell expansion and intraclonal diversification despite virus eradication in patients affected by hepatitis C virus-associated lymphoproliferative disorders.
Br J Haematol
; 203(2): 237-243, 2023 Oct.
Article
in English
| MEDLINE | ID: mdl-37491625
4.
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Br J Haematol
; 203(3): 416-425, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37580908
5.
IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling.
Proc Natl Acad Sci U S A
; 117(8): 4320-4327, 2020 02 25.
Article
in English
| MEDLINE | ID: mdl-32047037
6.
LINC01605 Is a Novel Target of Mutant p53 in Breast and Ovarian Cancer Cell Lines.
Int J Mol Sci
; 24(18)2023 Sep 06.
Article
in English
| MEDLINE | ID: mdl-37762037
7.
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
Br J Haematol
; 198(1): 103-113, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35277855
8.
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression.
Blood
; 135(15): 1244-1254, 2020 04 09.
Article
in English
| MEDLINE | ID: mdl-32006000
9.
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
Haematologica
; 107(11): 2685-2697, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-35484662
10.
Elastin MIcrofibriL INterfacer1 (EMILIN-1) is an alternative prosurvival VLA-4 ligand in chronic lymphocytic leukemia.
Hematol Oncol
; 40(2): 181-190, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34783040
11.
SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation
Haematologica
; 106(12): 3125-3135, 2021 Dec 01.
Article
in English
| MEDLINE | ID: mdl-33121237
12.
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
Haematologica
; 106(9): 2345-2353, 2021 09 01.
Article
in English
| MEDLINE | ID: mdl-32732360
13.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Article
in English
| MEDLINE | ID: mdl-33378569
14.
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.
Haematologica
; 105(6): 1613-1620, 2020 06.
Article
in English
| MEDLINE | ID: mdl-31582547
15.
VLA-4 Expression and Activation in B Cell Malignancies: Functional and Clinical Aspects.
Int J Mol Sci
; 21(6)2020 Mar 23.
Article
in English
| MEDLINE | ID: mdl-32210016
16.
[Early effects of attendance to the Friuli Venezia Giulia (Northern Italy) mammography screening programme on the incidence of advanced-stage breast cancer: a cohort study]. / Effetti precoci dell'adesione al programma di screening mammografico della Regione Friuli Venezia Giulia sull'incidenza del cancro della mammella in stadio avanzato: uno studio di coorte.
Epidemiol Prev
; 44(2-3): 145-153, 2020.
Article
in Italian
| MEDLINE | ID: mdl-32631014
17.
CD49d in chronic lymphocytic leukemia: a molecule with multiple regulation layers. Comment to "Sialylation regulates migration in chronic lymphocytic leukemia".
Haematologica
; 109(1): 362-363, 2024 Jan 01.
Article
in English
| MEDLINE | ID: mdl-37199129
18.
COVID-19 vaccination: Evaluation of humoral and cellular immunity after the booster dose in chronic lymphocytic leukemia patients.
Hematol Oncol
; 41(3): 559-562, 2023 08.
Article
in English
| MEDLINE | ID: mdl-36585917
19.
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Am J Hematol
; 98(7): E157-E160, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37067157
20.
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study.
Am J Hematol
; 98(2): E24-E27, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36349541